Samsung Biologics has agreed to acquire Swiss peptide CDMO PolyPeptide Group for approximately 1.46 billion Swiss francs $1.8 billion in an all-cash tender offer, its largest overseas acquisition. The deal, priced at 44.31 francs per share with a 40 percent premium, brings GLP-1 peptide API…
By Nam Hyun-woo
Samsung Biologics announced on July 20, 2026 that it will launch an all-cash public tender offer to acquire PolyPeptide Group, the Swiss peptide contract development and manufacturing organization, for approximately 1.46 billion Swiss francs, about $1.8 billion in U.S. dollars. The transaction is Samsung Biologics' largest overseas acquisition and its first entry into peptide therapeutics manufacturing, extending a business built on antibodies and antibody-drug conjugates ADCs . PolyPeptide's board of directors, chaired by Peter Wilden, unanimously recommended that shareholders accept the offer.
John Rim, chief executive officer of Samsung Biologics, framed the purchase as a broadening of the company's service base. "The acquisition reinforces our long-term growth strategy by broadening our service portfolio into peptides, including GLP-1 therapies, while further expanding our geographic reach across the United States, Europe and India."
The strategic logic runs through the metabolic drug market. GLP-1 receptor agonists for type 2 diabetes and obesity have become the most consequential class of medicines built by chemical synthesis rather than cell culture, and peptide active pharmaceutical ingredient API capacity has become a strategic asset. Rather than build peptide capability from the ground up, Samsung Biologics is paying for PolyPeptide's manufacturing expertise, its regulatory track record, and a plant network that no greenfield project could replicate quickly.
Samsung Biologics is one of the largest contract manufacturers of biologics by production capacity, with antibody plants serving a global roster of pharmaceutical sponsors. The PolyPeptide purchase does not merely add a product line. It changes the company's position from a biologics manufacturer that also performs conjugation to a multimodality supplier that covers chemical synthesis as well. For a contract development and manufacturing organization, modality breadth is a competitive defense: sponsors consolidate vendors, and a supplier that cannot handle a peptide program can lose the antibody and ADC programs attached to the same client.
J.P. Morgan is serving as Samsung Biologics' exclusive financial adviser on the transaction.
The offer values every outstanding share of PolyPeptide at 44.31 Swiss francs in cash. Samsung Biologics said the price represents a 40 percent premium over PolyPeptide's unaffected closing share price, measured before acquisition rumors involving the company emerged in April 2026. The baseline matters. Share prices move on rumor, and takeover documents conventionally anchor premiums to the pre-rumor price rather than to a price already inflated by speculation.
The all-cash structure carries its own signal. There is no stock component for PolyPeptide shareholders to value and no deferred consideration tied to how the peptide market performs after the deal. Sellers receive a fixed cash price per share, and the transaction's completion does not depend on the future performance of PolyPeptide's business. That simplicity concentrates attention on the price, the conditions, and the probability of closing.
Completion depends on shareholder participation. Samsung Biologics must secure acceptances representing at least two-thirds of PolyPeptide's shares, a bar well above a simple majority that gives minority holders real influence over the outcome. The company has one large commitment in hand: PolyPeptide's largest shareholder, which owns about 55.7 percent, has agreed to tender its stake. The holder's identity was not disclosed. On the arithmetic of the threshold, the remaining shareholders would need to deliver roughly 11 percentage points of acceptances on top of that anchor block for the condition to be satisfied.
The target is a long-established specialist. PolyPeptide is headquartered in Switzerland and operates manufacturing sites in Sweden, Belgium, France, the United States, and India. It has been in business for more than 70 years and has produced more than 1,000 therapeutic peptides over that history, a record spanning short hormones, metabolic peptides, and complex analogs.
After closing, Samsung Biologics intends to buy out the remaining minority shareholders and delist PolyPeptide from the SIX Swiss Exchange. The two-step structure, a public tender followed by a minority buyout and delisting, is the standard shape of a Swiss public takeover.
The formal tender offer will proceed under Swiss takeover law, the body of rules that governs public offers for shares of companies listed in Switzerland, including PolyPeptide on the SIX Swiss Exchange. Samsung Biologics plans to launch the formal offer at the end of August 2026. The procedure includes a defined offer period during which shareholders can tender their shares, a public offering document setting out the consideration, the conditions, and the timetable, and statutory rules governing acceptance and withdrawal.
The conditions attached to the deal are the acceptance condition, regulatory clearances, and other customary conditions. The announcement did not name the specific competition or foreign investment authorities that must approve the transaction. The cross-border structure makes review unavoidable: the acquirer is a South Korean company, the target is Swiss-listed, and the target's production assets sit in five countries across Europe, North America, and Asia. Antitrust scrutiny in the relevant jurisdictions and foreign investment screening in the countries where PolyPeptide operates are the clearances that the structure implies, even if the announcement left them unnamed.
The two-thirds acceptance condition is not arbitrary. In a Swiss public takeover, a bidder that reaches a sufficiently high ownership level can eliminate the residual minority through a squeeze-out. Requiring a supermajority of acceptances up front reduces the risk that a small group of holdout shareholders obstructs the delisting or forces a valuation dispute later. The condition also protects PolyPeptide's minority: the offer proceeds only if an overwhelming majority of the share capital supports it.
The timetable is compressed but not unusual. A formal launch at the end of August and an expected closing toward the end of 2026 leave a window of roughly four months for the offer period, the acceptance determination, and the receipt of clearances. Closing is a target, not a commitment. If the acceptance threshold is not met, if a regulator objects, or if a customary condition fails, the transaction does not complete.
The "customary conditions" language is worth parsing. In cross-border CDMO deals, such conditions typically include the accuracy of the seller's representations, the absence of a material adverse change in the target's business, and the receipt of third-party consents for contracts that change hands with the company. None of those were specified in the announcement, which means the first complete view of the condition set will come with the offer document at the end of August.
The post-closing steps follow Swiss practice. Once a bidder holds a sufficiently large position, it can initiate a squeeze-out of the residual minority, and Samsung Biologics' stated intention to buy out remaining shareholders and delist PolyPeptide from the SIX Swiss Exchange tracks that mechanism. From the formal launch onward, the offer documents and their administration fall under Swiss takeover law.
The scientific logic of the acquisition turns on how peptides are made, and how that differs from how antibodies are made. Antibodies are large proteins produced in living cells, typically mammalian cell culture, with molecular weights around 150 kilodaltons. Peptide drugs are smaller, chemically synthesized molecules; the GLP-1 receptor agonist semaglutide, for instance, is a 31-amino-acid peptide. Manufacturing a peptide API means building the chain by solid-phase peptide synthesis , coupling amino acids iteratively onto a resin, then cleaving the completed chain and purifying it to pharmaceutical grade.
That chemistry is exacting. Each coupling step must proceed to near-completion, because failures accumulate: deletion sequences, truncated chains, oxidized residues, and epimers all enter the product mixture. For peptides of 30 residues or more, the impurity burden rises with chain length, and chromatographic purification becomes a large share of cost of goods. Scaling a peptide from laboratory grams to the commercial volumes that metabolic disease drugs require is a process chemistry problem rather than a simple capacity problem. PolyPeptide's more than 70 years in operation and its catalog of more than 1,000 therapeutic peptides are descriptions of that accumulated knowledge: which resins, coupling reagents, deprotection conditions, and purification trains work for a given sequence, and which do not.
Capacity in peptide manufacturing is also not fungible with antibody capacity. Bioreactor volume is the unit of antibody production, and reactors can be expanded in known increments. Peptide output is constrained by synthesis equipment, purification train capacity, and, above all, by the process itself. A process that runs at low yield with a heavy impurity burden consumes far more capacity per kilogram of drug than a well-developed one, which is why process development skill, not just floor space, determines how much product a plant can ship.
The biology explains the commercial urgency around GLP-1 therapies . GLP-1, glucagon-like peptide-1, is an incretin hormone released by intestinal L cells in response to food intake. It amplifies glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and acts on central nervous system receptors to reduce appetite. Because insulin secretion is glucose-dependent, these drugs carry a comparatively low risk of hypoglycemia, which made them suitable for chronic use in broad patient populations. Engineered GLP-1 receptor agonists resist breakdown by dipeptidyl peptidase-4 and use modifications such as fatty acid acylation to bind albumin and extend half-life. Their use in type 2 diabetes and obesity has created demand for peptide API at a scale the industry had not previously required, and Rim's naming of GLP-1 therapies in the deal announcement ties the acquisition directly to that market.
Peptide synthesis also fits alongside what Samsung Biologics already operates. Antibody-drug conjugates require three production capabilities: the antibody itself, the cytotoxic payload, and the linker chemistry that joins them. Samsung Biologics' base is cell culture and conjugation; PolyPeptide's base is chemical synthesis. The declared result is an end-to-end multimodality CDMO platform spanning antibodies, ADCs, and peptide therapeutics, allowing a sponsor to place programs of different molecular classes with a single manufacturer and to move a candidate from early supply to commercial scale without changing contract partners.
For pharmaceutical sponsors, the deal consolidates peptide API capacity under a large biologics manufacturer, and that has two faces. A single provider able to handle a peptide program and, separately, an antibody or ADC program simplifies qualification, technology transfer, and supply agreements across a portfolio. The same consolidation removes an independent peptide CDMO from the market, which matters to developers who want competing options for a critical raw material. Peptide API is often the rate-limiting component of a peptide drug's supply chain, and concentration of that capacity shifts the negotiating position of every sponsor that needs…
Peptides referenced: Semaglutide, Glucagon, GLP-1.
Vendors referenced: Independent Peptide.
Related reading: Samsung Biologics Makes $1.8 Billion Bid to Acquire PolyPep, Samsung Biologics to Buy PolyPeptide in All-Cash Deal, Telehealth Visit Results in Prescription of Unapproved Peptides, Survey Shows Rise in Peptide Misinformation and Misuse in US.